© 1999 by European Society of Cardiology
Copyright © 1999, European Society of Cardiology
The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice
aThe Lipid Research Laboratory, Technion Faculty of Medicine, the Rappaport Institute for Research in the Medical Sciences, Haifa, Israel
bAnatomy Department, Technion, Haifa, Israel
cThe Laboratory of Biochemical Genetics and Metabolism, The Rockefeller University, New York, NY, USA
* Corresponding author. Tel.: +972-4-854-2059; fax: +972-4-854-2359 skeidar{at}rambam.health.gov.il
Objective: To investigate the possible mechanisms of the antiatherosclerotic effects of the angiotensin-converting enzyme (ACE) inhibitor, fosinopril, in apolipoprotein (apo) E deficient mice. Methods: Apo E deficient (E0) mice at the age of 8 weeks received either placebo or a high dose (25 mg/kg/d) of fosinopril supplemented in their drinking water. Results: After 12 weeks of treatment, fosinopril reduced the aortic lesion size by 70%, compared with the placebo group. At this dosage, fosinopril significantly reduced blood pressure from 93±2 mmHg before treatment to 70±2 mmHg at the end of the treatment period (P<0.005). Fosinopril also increased the resistance of the mice plasma low density lipoprotein (LDL) to CuSO4-induced oxidation, as shown by a 90% reduction in the LDL content of malondialdehyde (MDA) and also by a prolongation of the lag time required for the initiation of LDL oxidation (from 100 min in the placebo-treated mice to more than 240 min in the fosinopril-treated mice; P<0.001). In addition, fosinopril inhibited CuSO4-induced oxidation of LDL that was obtained from the aortas of the treated mice, as shown by an 18% and 37% reduction in the LDL content of lipid peroxides and hydroperoxy-cholesterol linoleate, respectively, compared with the placebo-treated mice (P<0.01). A low dosage of fosinopril (5 mg/kg/d) that was still adequate to reduce their plasma ACE activity and LDL propensity to lipid peroxidation was insufficient to lower their blood pressure. This dosage also reduced the aortic lesion size in the apo E deficient mice by 40% (P<0.01). Conclusions: The antiatherogenic effects of fosinopril in apo E deficient mice are due not only to blood pressure reduction but also to the direct inhibition of angiotensin II-dependent effects, which are probably also associated with the inhibition of LDL oxidation.
KEYWORDS Atherosclerosis; Apo E deficient mice; LDL oxidation; Angiotensin II; Blood pressure
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Ramkhelawon, J. Vilar, D. Rivas, B. Mees, R. de Crom, A. Tedgui, and S. Lehoux Shear Stress Regulates Angiotensin Type 1 Receptor Expression in Endothelial Cells Circ. Res., October 23, 2009; 105(9): 869 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kappert, O. Tsuprykov, J. Kaufmann, J. Fritzsche, I. Ott, M. Goebel, I. N. Bahr, P.-L. Hassle, R. Gust, E. Fleck, et al. Chronic Treatment With Losartan Results in Sufficient Serum Levels of the Metabolite EXP3179 for PPAR{gamma} Activation Hypertension, October 1, 2009; 54(4): 738 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kvakan, M. Kleinewietfeld, F. Qadri, J.-K. Park, R. Fischer, I. Schwarz, H.-P. Rahn, R. Plehm, M. Wellner, S. Elitok, et al. Regulatory T Cells Ameliorate Angiotensin II-Induced Cardiac Damage Circulation, June 9, 2009; 119(22): 2904 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh, P. C. Oh, and M. J. Quon Does reversal of oxidative stress and inflammation provide vascular protection? Cardiovasc Res, March 1, 2009; 81(4): 649 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Imayama, T. Ichiki, D. Patton, K. Inanaga, R. Miyazaki, H. Ohtsubo, Q. Tian, K. Yano, and K. Sunagawa Liver X Receptor Activator Downregulates Angiotensin II Type 1 Receptor Expression Through Dephosphorylation of Sp1 Hypertension, June 1, 2008; 51(6): 1631 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kojima, A. Kawakami, T. Takei, K. Nitta, and M. Yoshida Angiotensin-Converting Enzyme Inhibitor Attenuates Monocyte Adhesion to Vascular Endothelium through Modulation of Intracellular Zinc J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 855 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Suganuma, V. R. Babaev, M. Motojima, Y. Zuo, N. Ayabe, A. B. Fogo, I. Ichikawa, M. F. Linton, S. Fazio, and V. Kon Angiotensin Inhibition Decreases Progression of Advanced Atherosclerosis and Stabilizes Established Atherosclerotic Plaques J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2311 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bro, C. J. Binder, J. L. Witztum, K. Olgaard, and L. B. Nielsen Inhibition of the Renin-Angiotensin System Abolishes the Proatherogenic Effect of Uremia in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1080 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yvan-Charvet, P. Even, N. Lamande, P. Ferre, and A. Quignard-Boulange Prevention of Adipose Tissue Depletion during Food Deprivation in Angiotensin Type 2 Receptor-Deficient Mice Endocrinology, November 1, 2006; 147(11): 5078 - 5086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. L. Sales, G. K. Sukhova, M. A. Lopez-Ilasaca, P. Libby, V. J. Dzau, and R. E. Pratt Angiotensin Type 2 Receptor Is Expressed in Murine Atherosclerotic Lesions and Modulates Lesion Evolution Circulation, November 22, 2005; 112(21): 3328 - 3336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh, M. J. Quon, S. H. Han, W.-J. Chung, J. Y. Ahn, Y.-H. Seo, M. H. Kang, T. H. Ahn, I. S. Choi, and E. K. Shin Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive Patients Circulation, December 14, 2004; 110(24): 3687 - 3692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wassmann, T. Czech, M. van Eickels, I. Fleming, M. Bohm, and G. Nickenig Inhibition of Diet-Induced Atherosclerosis and Endothelial Dysfunction in Apolipoprotein E/Angiotensin II Type 1A Receptor Double-Knockout Mice Circulation, November 9, 2004; 110(19): 3062 - 3067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rosenhek, F. Rader, N. Loho, H. Gabriel, M. Heger, U. Klaar, M. Schemper, T. Binder, G. Maurer, and H. Baumgartner Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis Circulation, September 7, 2004; 110(10): 1291 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh, J. W. Son, J. Y. Ahn, D. S. Kim, D. K. Jin, H. S. Kim, S. H. Han, Y.-H. Seo, W.-J. Chung, W. C. Kang, et al. Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients Hypertension, August 1, 2004; 44(2): 180 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hayek, E. Pavlotzky, S. Hamoud, R. Coleman, S. Keidar, M. Aviram, and M. Kaplan Tissue Angiotensin-Converting-Enzyme (ACE) Deficiency Leads to a Reduction in Oxidative Stress and in Atherosclerosis: Studies in ACE-Knockout Mice Type 2 Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2090 - 2096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh, J. Y. Ahn, S. H. Han, D. S. Kim, D. K. Jin, H. S. Kim, M.-S. Shin, T. H. Ahn, I. S. Choi, and E. K. Shin Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients J. Am. Coll. Cardiol., September 3, 2003; 42(5): 905 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Singh and J. L. Mehta Interactions Between the Renin-Angiotensin System and Dyslipidemia: Relevance in the Therapy of Hypertension and Coronary Heart Disease Arch Intern Med, June 9, 2003; 163(11): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Brasier, A. Recinos III, and M. S. Eledrisi Vascular Inflammation and the Renin-Angiotensin System Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1257 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Imai, T. Shindo, K. Maemura, M. Sata, Y. Saito, Y. Kurihara, M. Akishita, J. Osuga, S. Ishibashi, K. Tobe, et al. Resistance to Neointimal Hyperplasia and Fatty Streak Formation in Mice With Adrenomedullin Overexpression Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1310 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kramer, J. Sunkomat, J. Witte, M. Luchtefeld, M. Walden, B. Schmidt, R. H. Boger, W.-G. Forssmann, H. Drexler, and B. Schieffer Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179 Circ. Res., April 19, 2002; 90(7): 770 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Keidar, R. Heinrich, M. Kaplan, and M. Aviram Oxidative stress increases the expression of the angiotensin-II receptor type 1 in mouse peritoneal macrophages Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 24 - 30. [Abstract] [PDF]
|
|
|
|
|
|
J. Chen, P. J. Kuhlencordt, J. Astern, R. Gyurko, and P. L. Huang Hypertension Does Not Account for the Accelerated Atherosclerosis and Development of Aneurysms in Male Apolipoprotein E/Endothelial Nitric Oxide Synthase Double Knockout Mice Circulation, November 13, 2001; 104(20): 2391 - 2394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Keidar, R. Heinrich, M. Kaplan, T. Hayek, and M. Aviram Angiotensin II Administration to Atherosclerotic Mice Increases Macrophage Uptake of Oxidized LDL: A Possible Role for Interleukin-6 Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1464 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Selzman, S. A. Miller, and A. H. Harken Therapeutic implications of inflammation in atherosclerotic cardiovascular disease Ann. Thorac. Surg., June 1, 2001; 71(6): 2066 - 2074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wassmann, U. Laufs, A. T. Baumer, K. Muller, K. Ahlbory, W. Linz, G. Itter, R. Rosen, M. Bohm, and G. Nickenig HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species Hypertension, June 1, 2001; 37(6): 1450 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kintscher, S. Wakino, S. Kim, E. Fleck, W. A. Hsueh, and R. E. Law Angiotensin II Induces Migration and Pyk2/Paxillin Phosphorylation of Human Monocytes Hypertension, February 1, 2001; 37(2): 587 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. d. Gasparo, P. Hess, B. Nuesslein-Hildesheim, P. Bruneval, and J.-P. Clozel Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 151 - 158. [Abstract] [PDF]
|
|
|
|
|
|
C. Kramer, J. Sunkomat, J. Witte, M. Luchtefeld, M. Walden, B. Schmidt, R. H. Boger, W.-G. Forssmann, H. Drexler, and B. Schieffer Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179 Circ. Res., April 19, 2002; 90(7): 770 - 776. [Abstract] [Full Text] [PDF]
|
|